MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT00507442
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT00500903
- Locations
- 🇺🇸
Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00343720
- Locations
- 🇧🇪
Hopital de Jolimont, Haine-Saint-Paul, Belgium
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 676
- Registration Number
- NCT00312845
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center, Burbank, California, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸St. Jude Heritage Medical Group, Fullerton, California, United States
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00298766
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸MSKCC, New York, New York, United States
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
- Conditions
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2008-06-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00298779
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
- Conditions
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00297921
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2011-02-17
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00283634
- Locations
- 🇺🇸
University of Tennesee, Knoxville, Tennessee, United States
MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00274248
- Locations
- 🇺🇸
The Dana Farber Cancer Institute, Boston, Massachusetts, United States
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00257114
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States